Patients receiving opioid maintenance treatment in primary care: Successful chronic hepatitis C care in a real world setting

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Seidenberg, André ^a,b   Rosemann, Thomas ^a   Senn, Oliver ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Private Practice   (Switzerland)

Author keywords

Hepatitis C; Methadone substitution; Primary care

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DRUG DEPENDENCE; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHADONE TREATMENT; OPIATE SUBSTITUTION TREATMENT; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SWITZERLAND; TREATMENT DURATION;

ADULT; ANALGESICS, OPIOID; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84871992334     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-9     Document Type: Article

References (30)

1. Mathei C, Buntinx F, van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western european countries: a systematic review. J Viral Hepat 2002, 9:157-173. 10.1046/j.1365-2893.2002.00339.x, 12010503.
2. Verna EC, Brown RS. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006, 10:919-940. 10.1016/j.cld.2006.08.012, 17164125.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965. 10.1016/S0140-6736(01)06102-5, 11583749.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982. 10.1056/NEJMoa020047, 12324553.
5. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
6. Narasimhan G, Sargios TN, Kalakuntla R, et al. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat 2006, 13:783-786. 10.1111/j.1365-2893.2006.00763.x, 17052279.
7. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005, 20:754-758. 10.1111/j.1525-1497.2005.0161.x, 1490173, 16050887.
8. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292.
9. Zanini B, Covolo L, Donato F, et al. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther 2010, 32:2139-2159. 10.1016/S0149-2918(11)00021-X, 21316533.
10. Bonkovsky HL, Tice AD, Yapp RG, et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008, 103:2757-2765. 10.1111/j.1572-0241.2008.02065.x, 18684176.
11. Fried R, Monnat M, Seidenberg A, et al. Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion 2008, 78:123-130. 10.1159/000173733, 19023207.
12. Huber M, Weber R, Oppliger R, et al. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005, 33:25-29. 10.1007/s15010-005-4043-2, 15750756.
13. Mauss S, Berger F, Goelz J, et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004, 40:120-124.
14. National Institutes of Health Consensus Development Conference Statement Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002, 36:S3-S20. National Institutes of Health Consensus Development Conference Statement.
15. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005, 77:81-86. 10.1016/j.drugalcdep.2004.07.002, 15607844.
16. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998, 93:515-532. 10.1046/j.1360-0443.1998.9345157.x, 9684390.
17. MacGowan RJ, Brackbill RM, Rugg DL, et al. Sex, drugs and HIV counseling and testing: a prospective study of behavior-change among methadone-maintenance clients in New England. AIDS 1997, 11:229-235. 10.1097/00002030-199702000-00014, 9030371.
18. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008, 103:1828-1836. 10.1111/j.1360-0443.2008.02323.x, 18778390.
19. Senn O, Seidenberg A, Rosemann T. Determinants of successful chronic hepatitis C case finding among patients receiving opioid maintenance treatment in a primary care setting. Addiction 2009, 104:2033-2038. 10.1111/j.1360-0443.2009.02766.x, 19922570.
20. Seidenberg A, Peng M, Custer R. Prinzipien der sicheren opioidverordnung 2002, Bern: Bundesamt für Gesundheit.
21. Donovan DM, Bigelow GE, Brigham GS, et al. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction 2012, 107:694-708. 10.1111/j.1360-0443.2011.03473.x, 3537825, 21781202.
22. Irving WL, Smith S, Cater R, et al. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J Viral Hepat 2006, 13:264-271. 10.1111/j.1365-2893.2005.00698.x, 16611193.
23. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007, 56:385-389. 10.1136/gut.2006.099150, 1856823, 17005764.
24. Hansen N, Obel N, Christensen PB, et al. Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. J Viral Hepat 2009, 16:659-665. 10.1111/j.1365-2893.2009.01126.x, 19486467.
25. Prasad L, Spicher VM, Zwahlen M, et al. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 2007, 36:731-737. 10.1093/ije/dym096, 17693458.
26. Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol 2011, 106:1777-1786. 10.1038/ajg.2011.219, 21769136.
27. Pelet A, Doll S, Huissoud T, et al. Methadone maintenance treatment in the Swiss Canton of Vaud: demographic and clinical data on 1,782 ambulatory patients. Eur Addict Res 2005, 11:99-106. 10.1159/000083039, 15785071.
28. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011, 8:257-264.
29. Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010, 376:1441-1442. 10.1016/S0140-6736(10)61497-3, 20951421.
30. Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755. 10.1002/hep.23220, 19824079.